← Leaderboards
Shaheed Vally Omar
Columbia University Health Sciences
$759,071
Attributed
$2,277,213
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $832.2K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,277,213 · 1
By mechanism
R01$2,277,213 · 1
Top collaborators
- Neel Rajnikant Gandhi3 shared
- Barun Mathema3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Neel Rajnikant Gandhi$17,446,737
- Anne-Catrin Uhlemann$11,456,359
- Thomas Howe McConville$962,280
- Nesri Padayatchi$1,344,210
- Sumit Mohan$7,078,024
Others in their field
Other Rising Stars on “Cellular Targeting”
- Sabrina Paganoni · Massachusetts General Hospital$9,673,541
- Suma Babu · Massachusetts General Hospital$9,673,541
- Yanling Wang · Rush University Medical Center$5,926,468
- Joshua D. Wythe · Baylor College Of Medicine$3,966,787
- Suna Onengut · University Of Virginia$3,651,184
- Timothy I Richardson · Indiana University Indianapolis$3,602,073
Research focus
Cellular TargetingClonalityCombined Modality TherapyCountryDiagnostic AssayDoseDrug RepurposingDrug ResistanceDrug Resistance In TuberculosisEarly IdentificationEffectivenessEnsureEpidemicEpidemiologyEvolutionExhibitsExtensive Drug ResistanceExtreme Drug Resistant TuberculosisGenesGenetic AnalysisGenetic PolymorphismGenetic VariationGenome SequencingBiological
Grant awards (3)
Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa$722,084
R01 · FY2025 · AI
Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa$722,947
R01 · FY2024 · AI
Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa$832,182
R01 · FY2023 · AI